12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Spirogen preclinical data

In mouse xenograft models of breast cancer and hematological tumors, a series of trastuzumab antibody-drug conjugates (ADCs) containing cytotoxic pyrrolobenzodiazepine (PBD) dimer drug linkers produced durable complete regressions and led...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >